Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

NCT03440385 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT03440385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03440385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
March 7, 2018
Completion date
November 21, 2023
Enrollment
606 (actual)
Sites
368

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease